A loved one waking you with loud snoring, followed by gasping and choking sounds, might signal more than minor sleep ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

Between 30-50% of adults with hypertension have OSA, and this number increases to between 70-80% in adults with resistant hypertension. Additionally, untreated moderate-to-severe OSA increases the ...

Tirzepatide is the active ingredient in Zepbound, the FDA approved prescription medicine for Obstructive Sleep Apnea.

For individuals with mmOSA, CRP levels were associated with hypertension risk and insulin resistance among those aged less than 60 years.

Zepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, ...

“For obese individuals with moderate to severe sleep apnea, this new treatment option ... given that loud snoring and gasping for air are primary symptoms,” she said. Dr. William Lu, medical ...

both of which found that Zepbound helps reduce sleep apnea symptoms in some patients by aiding weight loss. Both studies monitored obese adults with moderate to severe sleep apnea over a 52-week ...

The FDA suggests that prescribed users also reduce their calorie intake and increase their exercise The weight loss drug Zepbound, generically known as tirzepatide, is also now an approved medication ...

In a news release published Dec. 20, the FDA stated that Zepbound, a glucagon-like peptide-1 receptor agonist, was cleared to treat moderate-to ... that their OSA symptoms resolved. FDA approval for ...